Traumagel

Traumagel is a plant-based, hydrogel hemostatic agent developed by Cresilon for the rapid control of moderate to severe external bleeding. It is supplied as a sterile, prefilled 30 mL syringe and requires no preparation before use. The gel consists of a proprietary combination of sodium alginate (a polyanionic polymer) and poly N-acetyl-D-glucosamine (a polycationic polymer), forming a viscous hydrogel in which chitosan granules are suspended. When applied directly to the source of bleeding, Traumagel rapidly adheres to the wound site and forms a mechanical barrier that stops blood flow within seconds—often less than 10 seconds in healthy patients—allowing endogenous clot formation without becoming incorporated into the fibrin clot itself. The product must be removed within 24 hours using saline lavage and gauze. Traumagel received FDA 510(k) clearance in August 2024 for temporary external use in controlling moderate to severe bleeding and is intended for use by medical professionals including EMS providers, trauma centers, military medics, and emergency departments[1][2][3][5][7][8].

Brand names

Traumagel

Other names

TRAUMAGELCresilon Hemostatic Gel (distinct earlier product)plant-based hemostatic gel